Hameed M, Orrell RW, Cobbold M, Goldspink G, Harridge SDR
SURMOUNT-1: Tirzepatide for Obesity The SURMOUNT-1 trial (NEJM, 2022) studied tirzepatide weight loss in 2,539 adults with obesity (without diabetes) over 72 weeks: STEP 1: Semaglutide for Obesity The STEP 1 trial (NEJM, 2021) studied semaglutide 2.4mg in 1,961 adults with obesity (without diabetes) over 68 weeks: Cross-Trial Summary Comparing across trials (with the caveat that indirect comparison has limitations): tirzepatide 15mg produced about 6 percentage points more weight loss than semaglutide 2.4mg over similar timeframes
However, the RCT studies, case reports, and the FAERS database case all highlighted that we should be aware of co-administered neuropsychotropic drugs that may associated with SSIBs
Medicare Part D insured patients with type 2 diabetes may qualify for Extra Help to get a 30-day supply of Rybelsus for $10.35 only from Novo Nordisk
~ AlphaMD Ashwagandha (Withania somnifera) is a popular adaptogenic herb that has been used for centuries in Ayurvedic medicine to enhance overall health and vitality